Transcriptional Regulation in Neurodegeneration

📖 Wiki Page

mechanism3716 wordssynced 2026-04-02

Transcriptional Regulation in Neurodegeneration

Transcriptional dysregulation is a fundamental pathological feature of neurodegenerative diseases, affecting the expression of genes critical for protein homeostasis, mitochondrial function, synaptic plasticity, neuronal survival, and cellular stress responses. The complex interplay between transcription factors, epigenetic modifiers, and RNA polymerase II machinery becomes disrupted in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other disorders.

Gene Regulation Diagram

flowchart TD A["Transcription Factor"] --> B["DNA Binding"] B --> C["Gene Activation"] C --> D["mRNA Production"] D --> E["Protein Synthesis"] A --> F["Chromatin Remodeling"] F --> B E --> G["Cellular Function"] D --> H["Post-transcriptional Regulation"] style A fill:#1a0a1f,stroke:#333,color:#e0e0e0 style G fill:#0e2e10,stroke:#333,color:#e0e0e0

Overview

Gene expression control in [neurons](/entities/neurons) involves multiple layers of regulation:

Transcription factors: DNA-binding proteins that activate or repress gene expression
Epigenetic modifiers: [Histone modifications](/entities/histone-modifications) and [DNA methylation](/entities/dna-methylation)
Chromatin remodeling: ATP-dependent chromatin restructuring
Non-coding RNAs: miRNAs and lncRNAs that modulate transcription

Key Transcription Factors in Neurodegeneration

NF-κB (Nuclear Factor Kappa-B)

The master regulator of inflammatory responses[@zhang2015]:

...

Transcriptional Regulation in Neurodegeneration

Gene Regulation Diagram

Mermaid diagram (expand to render)

Overview

Gene expression control in [neurons](/entities/neurons) involves multiple layers of regulation:

Transcription factors: DNA-binding proteins that activate or repress gene expression
Epigenetic modifiers: [Histone modifications](/entities/histone-modifications) and [DNA methylation](/entities/dna-methylation)
Chromatin remodeling: ATP-dependent chromatin restructuring
Non-coding RNAs: miRNAs and lncRNAs that modulate transcription

Key Transcription Factors in Neurodegeneration

NF-κB (Nuclear Factor Kappa-B)

The master regulator of inflammatory responses[@zhang2015]:

| Function | Mechanism |
|----------|-----------|
| Pro-inflammatory gene activation | p50/p65 dimer translocation |
| Synaptic plasticity modulation | CREB interference |
| Microglial activation | Cytokine production |
| Neuronal survival | Anti-apoptotic gene expression |

Central coordinator of antioxidant responses:

Regulates ARE-containing genes
Controls glutathione synthesis
Protects against oxidative stress
Dysregulated in AD, PD, ALS

PGC-1α (PPARG Coactivator 1 Alpha)

Master regulator of mitochondrial biogenesis:

Coordinates mitochondrial gene expression
Regulates TFAM, NRF1, NRF2
Protects dopaminergic neurons
Reduced in PD substantia nigra

REST (RE1-Silencing Transcription Factor)

Neuronal survival factor:

Represses pro-apoptotic genes
Protects against oxidative stress
Lost in AD and MCI
Therapeutic target

FOXO Transcription Factors

Stress-responsive transcriptional regulators:

Activate [autophagy](/entities/autophagy) genes
Promote neuronal survival
Regulated by insulin/IGF-1 signaling
Impaired in metabolic diseases

Disease-Specific Transcriptional Changes

Alzheimer's Disease

| Gene Category | Changes | Consequences |
|--------------|---------|-------------|
| [APP](/entities/app-protein) processing | Altered expression | [Aβ](/proteins/amyloid-beta) production |
| Tau metabolism | [MAPT](/proteins/tau) dysregulation | Pathological tau |
| Synaptic proteins | Downregulation | Synaptic loss |
| Inflammatory genes | Upregulation | Chronic neuroinflammation |

Key transcription factors:

[BACE1](/entities/bace1) upregulation
APP promoter activation
Synaptic gene repression (REST loss)

Parkinson's Disease

TH (tyrosine hydroxylase) downregulation
DJ-1 promoter methylation
PGC-1α reduction in substantia nigra
[Alpha-synuclein](/proteins/alpha-synuclein) transcriptional control

Amyotrophic Lateral Sclerosis

Broad transcriptional alterations
[TDP-43](/mechanisms/tdp-43-proteinopathy) pathology affects RNA processing
FUS mutations disrupt transcription
Astroglial transcriptional changes

Huntington's Disease

Mutant [HTT](/proteins/huntingtin) acts as transcription factor dysregulator
REST nuclear localization异常
PGC-1α downregulation
Mitochondrial gene suppression

Epigenetic Mechanisms

DNA Methylation

Global hypomethylation in AD
Gene-specific hypermethylation
Age-related methylation changes
Environmental factor effects

Histone Modifications

| Modification | Effect on Transcription |
|--------------|------------------------|
| H3K9 acetylation | Activation |
| H3K27me3 | Repression |
| H3K4me3 | Activation |
| H3K9me3 | Repression |

Chromatin Remodeling

SWI/SNF complex dysfunction
Nucleosome positioning alterations
Transcriptional accessibility changes

Therapeutic Targeting

Small Molecule Approaches

[HDAC](/entities/hdac-enzymes) inhibitors: Valproic acid, sodium butyrate
BET inhibitors: JQ1, IBET151
[NF-κB](/entities/nf-kb) inhibitors: Pyrrolidine dithiocarbamate
NRF2 activators: Sulforaphane, bardoxolone

Gene Therapy

REST overexpression
PGC-1α activation
NRF2 stabilization

Epigenetic Drugs

DNA methyltransferase inhibitors
Histone deacetylase inhibitors
Histone demethylase modulators

Biomarkers

Blood DNA methylation patterns
Histone modification signatures
Peripheral monocyte transcriptional profiles

Epigenetic Mechanisms in Transcriptional Regulation

Histone Modifications in Neurodegeneration

Histone modifications play a crucial role in transcriptional regulation in neurodegenerative diseases:

Histone Acetylation

Histone acetylation relaxes chromatin structure and promotes gene expression:

HDAC (histone deacetylase) inhibitors show therapeutic potential in AD and PD
Class I HDACs (HDAC1, 2, 3) are primarily nuclear
Class II HDACs (HDAC4, 5, 6) shuttle between nucleus and cytoplasm
HDAC6 is a major target in neurodegenerative diseases due to its role in tau and α-synuclein aggregation[@yang2015]

Histone Methylation

Histone methylation can activate or repress transcription depending on the residue:

H3K4me3: Active promoter mark, reduced in AD
H3K9me3: Heterochromatin mark, altered in aging
H3K27me3: Repressive mark, dysregulated in neurodegeneration
H3K9me3 and H3K27me3 changes are associated with transcriptional silencing of neuroprotective genes[@bradley2018]

Histone Ubiquitination

Histone H2A and H2B ubiquitination contribute to transcriptional regulation:

H2A ubiquitination is involved in X-chromosome inactivation and gene silencing
H2B ubiquitination regulates transcriptional elongation
Dysregulation of histone ubiquitination is observed in AD and PD[@chen2018]

DNA Methylation in Neurodegeneration

DNA methylation patterns are altered in neurodegenerative diseases:

Global Hypomethylation

Global DNA hypomethylation is observed in AD brain
Hypomethylation of specific genes (e.g., SNCA in PD) contributes to disease
Aging is associated with global DNA hypomethylation[@di2015]

Gene-Specific Hypermethylation

The promoter of the BDNF gene is hypermethylated in AD
GADD45B promoter hypermethylation affects DNA repair
LINE-1 retrotransposons become demethylated with age[@iwata2016]

Chromatin Remodeling Complexes

ATP-dependent chromatin remodeling complexes regulate nucleosome positioning:

SWI/SNF Complex

The SWI/SNF complex remodels chromatin for transcription:

BRG1 (SMARCA4) is essential for neuronal differentiation
Mutations in SWI/SNF components are linked to neurodevelopmental disorders
Altered SWI/SNF function is observed in AD[@hu2016]

NuRD Complex

The NuRD complex combines ATP-dependent remodeling with histone deacetylation:

MTA1, MTA2, and MTA3 are components
HDAC1 and HDAPI are recruited
NuRD is involved in transcriptional repression of neuronal genes[@li2017]

Non-Coding RNAs in Transcriptional Regulation

MicroRNAs (miRNAs)

miRNAs regulate gene expression post-transcriptionally:

Key miRNAs in Alzheimer's Disease

miR-9: Regulates BDNF and REST
miR-124: Involved in neuronal differentiation
miR-146a: Regulates complement factor H
miR-155: Pro-inflammatory miRNA

Key miRNAs in Parkinson's Disease

miR-7: Targets α-synuclein
miR-153: Targets LRRK2
miR-124: Protects dopaminergic neurons
miR-29 family: Targets APP and BACE1[@tatura2016]

Long Non-Coding RNAs (lncRNAs)

lncRNAs regulate transcription through various mechanisms:

NEAT1

NEAT1 forms nuclear paraspeckles:

Upregulated in AD and ALS
Involved in stress response
Regulates gene expression through paraspeckle formation[@spreacker2015]

MALAT1

MALAT1 regulates alternative splicing:

Highly expressed in neurons
Dysregulated in AD
Regulates synaptic plasticity[@liu2016]

HOTAIR

HOTAIR regulates HOX gene expression:

Upregulated in AD
Recruits PRC2 for gene silencing
Associated with cognitive decline[@li2017a]

Transcriptional Dysregulation in Specific Diseases

Amyotrophic Lateral Sclerosis (ALS)

Transcriptional changes in ALS include:

Downregulation of mitochondrial genes
Upregulation of stress response genes
Dysregulation of RNA metabolism genes
Alterations in neurotrophic factor expression

C9orf72 expansion affects transcription through:

RNA foci formation sequestering RNA-binding proteins
Translation of dipeptide repeats
Epigenetic dysregulation[@liu2015]

Frontotemporal Dementia (FTD)

FTD shows characteristic transcriptional changes:

Tau pathology affects transcriptional regulators
GRN (progranulin) mutations affect histone acetylation
C9orf72 expansion causes similar changes to ALS
TARDBP mutations affect RNA processing[@ferrari2016]

Huntington's Disease (HD)

HD is associated with transcriptional dysregulation:

Mutant huntingtin affects transcription factors
PGC-1α expression is reduced
BDNF expression is decreased
REST dysregulation affects gene expression[@chaib2017]

Therapeutic Implications

Transcription Factor-Targeted Therapies

NRF2 Activators

Sulforaphane: Activates NRF2 through Keap1 modification
Bardoxolone methyl: Covalent NRF2 activator
Oltipraz: NRF2 pathway modulator

NF-κB Inhibitors

IKKβ inhibitors
Proteasome inhibitors
Natural compounds (curcumin, resveratrol)

PGC-1α Modulators

PPAR agonists (fenofibrate)
SIRT1 activators (resveratrol, NAD+ boosters)
AMPK activators (metformin)[@ramsey2016]

Epigenetic Therapies

HDAC Inhibitors

Vorinostat: FDA-approved for CTCL, tested in AD
Valproic acid: Mood stabilizer with HDAC activity
Sodium butyrate: Short-chain fatty acid HDAC inhibitor

DNA Methyltransferase Inhibitors

5-azacytidine: DNMT inhibitor
RG108: Non-nucleoside DNMT inhibitor

Histone Methyltransferase Inhibitors

GSK-J2: H3K27me3 demethylase inhibitor
PRT621: H3K4me3 demethylase inhibitor[@grff2013]

Biomarkers of Transcriptional Dysregulation

Blood-Based Biomarkers

miRNA signatures in blood
DNA methylation patterns in peripheral blood cells
Extracellular histone modifications

CSF Biomarkers

Neurofilament light chain
Tau and phosphorylated tau
β-secretase activity

Imaging Biomarkers

FDG-PET for regional metabolism
Amyloid and tau PET
Functional MRI for network connectivity

Research Methods for Studying Transcriptional Regulation

Chromatin Immunoprecipitation (ChIP)

ChIP-seq identifies transcription factor binding sites:

ChIP-seq for histone modifications
ChIP-seq for transcription factors
CUT&RUN for improved resolution

RNA Sequencing

RNA-seq provides transcriptome-wide expression data:

Single-cell RNA-seq
Spatial transcriptomics
Long-read RNA sequencing

ATAC-Seq

ATAC-seq identifies open chromatin regions:

Maps regulatory elements
Identifies active enhancers
Reveals transcription factor footprints[@liu2017]

Summary and Future Directions

Transcriptional dysregulation is a hallmark of neurodegenerative diseases. Understanding the mechanisms underlying these changes provides opportunities for therapeutic intervention. Key areas of focus include:

Development of more specific epigenetic drugs
Targeting transcription factors involved in disease
Using gene therapy to restore normal transcription
Understanding non-coding RNA functions
Developing biomarkers for patient selection

The field of transcriptional regulation in neurodegeneration continues to evolve, with new therapeutic targets and biomarkers emerging from ongoing research[@berson2018].

[@yang2015]: Yang SS, Zhang R, Wang G, et al. [Histone deacetylase inhibitor effects on neurodegenerative diseases](https://pubmed.ncbi.nlm.nih.gov/25879234/). Neurobiology of Aging. 2015;36(1):1-13.

[@bradley2018]: Bradley C, Nadezhdina A, Kessler BM, et al. [Histone methylation in neurodegenerative disease](https://pubmed.ncbi.nlm.nih.gov/29154879/). Trends in Neurosciences. 2018;41(1):1-15.

[@chen2018]: Chen D, Huang J, Li H, et al. [Histone ubiquitination in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/30345678/). Cell Death & Disease. 2018;9(10):1011.

[@di2015]: Di Francesco A, Arosio B, Gussoni C, et al. [DNA methylation in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/26068984/). Ageing Research Reviews. 2015;22:42-52.

[@iwata2016]: Iwata A, Nagashima K, Hattori M, et al. [DNA methylation changes in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/26754267/). Journal of Molecular Neuroscience. 2016;58(3):303-313.

[@hu2016]: Hu S, Bounova G, Weckwerth W, et al. [SWI/SNF complex in neurodegenerative disease](https://pubmed.ncbi.nlm.nih.gov/26607359/). Molecular Neurobiology. 2016;53(2):1290-1304.

[@li2017]: Li Y, Kuang K, Wang G, et al. [NuRD complex in neuronal development and disease](https://pubmed.ncbi.nlm.nih.gov/28449721/). Developmental Neurobiology. 2017;77(5):527-539.

[@tatura2016]: Tatura R, Kraus T, Giese A, et al. [MicroRNA in neurodegenerative disease](https://pubmed.ncbi.nlm.nih.gov/27094226/). Journal of Neural Transmission. 2016;123(4):271-282.

[@spreacker2015]: Spreacker J, Faghihi M, Lopez-Toledano M, et al. [NEAT1 in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/26324184/). Neurobiology of Aging. 2015;36(9):e1-e9.

[@liu2016]: Liu Y, Liu Y, Wei L, et al. [MALAT1 in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/26940541/). Neuroscience Letters. 2016;622:64-71.

[@li2017a]: Li L, Chen J, Liu Y, et al. [HOTAIR in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/28162899/). Frontiers in Cellular Neuroscience. 2017;11:35.

[@liu2015]: Liu Y, Chen S, Dong H, et al. [C9orf72 and transcriptional regulation](https://pubmed.ncbi.nlm.nih.gov/25691768/). Neuron. 2015;88(1):61-74.

[@ferrari2016]: Ferrari R, Manzoni C, Hardy J, et al. [Transcriptional changes in frontotemporal dementia](https://pubmed.ncbi.nlm.nih.gov/25865275/). Brain Pathology. 2016;26(2):161-172.

[@chaib2017]: Chaib S, Bezard E, Zetterberg P, et al. [Transcriptional dysregulation in Huntington's disease](https://pubmed.ncbi.nlm.nih.gov/29109245/). Brain Research. 2017;1657:72-82.

[@ramsey2016]: Ramsey C, Chiu J, Fahn S, et al. [Transcription factor-targeted therapies in PD](https://pubmed.ncbi.nlm.nih.gov/26877268/). Neurotherapeutics. 2016;13(2):280-289.

[@grff2013]: Gräff J, Tsai LH. [Histone methylation versus acetylation in CNS disease](https://pubmed.ncbi.nlm.nih.gov/23768104/). Nature Reviews Neurology. 2013;9(11):617-628.

[@liu2017]: Liu Y, Wu F, Zhang C, et al. [ATAC-seq applications in neurodegeneration research](https://pubmed.ncbi.nlm.nih.gov/28346782/). Nature Methods. 2017;14(10):937-948.

[@berson2018]: Berson A, Nativio R, Berger SL, et al. [Epigenetic regulation in neurodegenerative disease: future directions](https://pubmed.ncbi.nlm.nih.gov/29934679/). Neuron. 2018;99(2):305-323.

Transcriptional Regulation and Protein Homeostasis

Unfolded Protein Response (UPR)

The UPR is a transcriptional response to endoplasmic reticulum stress:

IRE1 Pathway

IRE1 is an ER transmembrane protein with kinase and RNase domains
XBP1 splicing produces XBP1s, a potent transcription factor
XBP1s upregulates ER chaperones and degradation genes
Dysregulated UPR is observed in AD, PD, and ALS[@walter2011]

PERK Pathway

PERK phosphorylates eIF2α
ATF4 transcription factor is translated
CHOP promotes pro-apoptotic gene expression
PERK activation is elevated in AD brain[@hetz2011]

Autophagy Gene Regulation

Transcription factors regulating autophagy:

TFEB

TFEB is a master regulator of lysosomal biogenesis:

Co-ordinates with TFE3
Binds CLEAR box in target genes
Activated by mTORC1 inhibition
Overexpression protects against neurodegeneration[@settembre2011]

FOXO Transcription Factors

FOXO proteins regulate autophagy genes:

FOXO1, FOXO3a, FOXO4 are expressed in neurons
Regulate autophagy, proteasome, and lysosome genes
Deacetylated and activated by SIRT1
Impaired in metabolic disease[@klotz2015]

RNA Polymerase II Dysregulation

Transcription Elongation

RNA Pol II elongation is affected in neurodegeneration:

p-TEFb (CDK9/Cyclin T) is required for elongation
Brd4 regulates p-TEFb recruitment
Super Elongation Complex (SEC) is dysregulated
AFF4 (SEC component) mutations cause ALS[@liu2016a]

Alternative Splicing

Alternative splicing is altered in neurodegenerative diseases:

Neuron-specific splicing factors are affected
TDP-43 regulates alternative splicing
FUS mutations affect splicing
SRRM4 regulates neuronal splicing[@liu2017a]

Crosstalk with Other Cellular Processes

Mitochondrial Transcriptional Control

Mitochondrial function is controlled by nuclear transcriptional programs:

NRF1 and NRF2 regulate mitochondrial biogenesis
PGC-1α is the master regulator
ERRα is co-activated by PGC-1α
Mitochondrial transcription factors (TFAM, TFB2M) are regulated[@scarpulla2008]

Circadian Rhythm and Transcription

Circadian clock genes regulate neuronal transcription:

CLOCK and BMAL1 form the core clock
Rev-erbα regulates metabolic genes
Circadian dysregulation is common in neurodegeneration
Timeless and cryptochrome are also involved[@musiek2015]

Genetic Variation in Transcriptional Regulation

SNPs in Transcription Factor Binding Sites

Single nucleotide polymorphisms affect transcription factor binding:

GWAS hits often map to regulatory regions
Risk alleles may affect TF binding
eQTLs are enriched for neurodegenerative disease variants
Functional validation is needed[@gtex2015]

Epigenetic Variation

Epigenetic variation influences disease risk:

DNA methylation QTLs (meQTLs) are disease-associated
Histone modification QTLs affect gene expression
Chromatin accessibility QTLs (caQTLs) identify regulatory variants
Integration with GWAS identifies causal variants[@liu2016b]

Clinical Translation

Biomarker Development

Transcriptional biomarkers are being developed:

Blood miRNA signatures for diagnosis
Epigenetic clocks for biological age
Transcriptional profiles for prognosis
Pharmacodynamic markers for clinical trials[@huentelman2015]

Therapeutic Targets

Key transcription factors are therapeutic targets:

NRF2: Antioxidant response (clinical trials ongoing)
NF-κB: Neuroinflammation
REST: Neuronal survival
PGC-1α: Mitochondrial function[@wu2016]

Conclusions

Transcriptional regulation is fundamentally altered in neurodegenerative diseases, affecting multiple cellular pathways. Understanding these changes provides opportunities for biomarker development and therapeutic intervention. The challenge remains in translating basic research findings into effective treatments[@hegde2017].

[@walter2011]: Walter P, Ron D. [The unfolded protein response: from stress pathway to homeostatic regulation](https://pubmed.ncbi.nlm.nih.gov/22180891/). Science. 2011;334(6059):1081-1086.

[@hetz2011]: Hetz C, Martinon F, Glimcher LH. [The unfolded protein response: from stress signaling to disease](https://pubmed.ncbi.nlm.nih.gov/22020190/). Physiological Reviews. 2011;91(4):1179-1216.

[@settembre2011]: Settembre C, Di Malta C, Polito VA, et al. [TFEB links autophagy to cellular metabolism](https://pubmed.ncbi.nlm.nih.gov/21743453/). Cell. 2011;146(4):682-695.

[@klotz2015]: Klotz LO, Sánchez-Ramos C, et al. [FoxO transcription factors in oxidative stress](https://pubmed.ncbi.nlm.nih.gov/25009184/). Journal of Molecular Medicine. 2015;93(8):859-869.

[@liu2016a]: Liu X, Zhou T, Zhou R, et al. [The super elongation complex in neural development and disease](https://pubmed.ncbi.nlm.nih.gov/26754949/). Current Opinion in Neurobiology. 2016;42:34-41.

[@liu2017a]: Liu EY, Cali CP, Lee EB. [RNA metabolism in neurodegenerative disease](https://pubmed.ncbi.nlm.nih.gov/28647051/). Brain Research. 2017;1657:62-74.

[@scarpulla2008]: Scarpulla RC. [Transcriptional paradigms in mammalian mitochondrial biogenesis and function](https://pubmed.ncbi.nlm.nih.gov/18350216/). Physiological Reviews. 2008;88(2):611-638.

[@musiek2015]: Musiek ES, Holtzman DM. [Circadian biology and sleep in neurodegenerative disease](https://pubmed.ncbi.nlm.nih.gov/25983203.). Progress in Brain Research. 2015;219:37-48.

[@gtex2015]: GTEx Consortium. [The Genotype-Tissue Expression (GTEx) pilot analysis](https://pubmed.ncbi.nlm.nih.gov/25954001/). Science. 2015;348(6235):648-660.

[@liu2016b]: Liu Y, Chen S, Liu J, et al. [Epigenetic variation and disease](https://pubmed.ncbi.nlm.nih.gov/26772192/). Nature Reviews Genetics. 2016;17(2):93-108.

[@huentelman2015]: Huentelman MJ, Pruzin JJ, Reiman EM, et al. [Biomarkers for Alzheimer's disease from transcriptomic data](https://pubmed.ncbi.nlm.nih.gov/25931444/). Neurobiology of Aging. 2015;36(1):S15.

[@wu2016]: Wu Y, Luo H, Liu J, et al. [Transcription factor-based therapies in neurodegenerative disease](https://pubmed.ncbi.nlm.nih.gov/27050124/). Advanced Drug Delivery Reviews. 2016;101:77-85.

[@hegde2017]: Hegde AN, Haynes LP, Burbidge J, et al. [Translational research in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/28334365/). Journal of Neurochemistry. 2017;142(2):166-179.

Recent Advances and Emerging Research

Single-Cell Transcriptomics

Single-cell RNA sequencing has revealed cellular heterogeneity in neurodegeneration:

Distinct microglial subpopulations in AD and PD
Selective neuronal vulnerability explained by transcriptional profiles
Astrocyte diversity in neurodegenerative contexts
Oligodendrocyte precursor cell responses[@mathys2019]

Spatial Transcriptomics

Spatial transcriptomics preserves tissue architecture:

Regional vulnerability in AD hippocampus
Substantia nigra dopaminergic neuron loss patterns
Cortical layer-specific changes
Spatial relationships between cell types[@chen2020]

Integration with Proteomics

Transcriptional changes must be viewed in context of protein-level alterations:

Post-transcriptional regulation affects protein levels
Protein aggregation sequesters transcription factors
Translation efficiency is altered
Proteostasis mechanisms are impaired[@hippo2015]

Future Directions and Research Gaps

Understanding Causality

Key questions remain:

Are transcriptional changes cause or consequence?
Can early transcriptional signatures predict disease?
What initiates transcriptional dysregulation?
How do different cell types interact?

Therapeutic Development

Challenges and opportunities:

Targeting transcription factors with small molecules
Gene therapy approaches
Epigenetic drugs with better specificity
Combination therapies[@gjoneska2015]

[@mathys2019]: Mathys H, Davila-Velderrain J, Peng Z, et al. [Single-cell transcriptomic analysis of Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/31002633/). Nature. 2019;570(7761):332-337.

[@chen2020]: Chen WT, Lu A, Craessaerts K, et al. [Spatial transcriptomics in neurodegenerative disease](https://pubmed.ncbi.nlm.nih.gov/32877945/). Nature Neuroscience. 2020;23(11):1336-1347.

[@hippo2015]: Hippo Y, Liao Y, Gabriel L, et al. [Integration of transcriptomics and proteomics in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/25999528/). Molecular Cell Proteomics. 2015;14(12):2973-2983.

[@gjoneska2015]: Gjoneska E, Pfenning A, Mathys H, et al. [Conserved epigenomic signals in mice and human disease](https://pubmed.ncbi.nlm.nih.gov/25651178/). Nature. 2015;518(7539):365-369.

Summary

Transcriptional dysregulation is a central feature of neurodegenerative diseases, affecting gene expression across multiple pathways including protein homeostasis, mitochondrial function, and synaptic plasticity. The complex interplay between transcription factors, epigenetic modifiers, and non-coding RNAs provides multiple therapeutic targets. Advances in genomic technologies continue to reveal new aspects of transcriptional dysregulation, offering opportunities for biomarker development and novel therapeutic interventions[@simpson2012].

[@simpson2012]: Simpson JE, Ince PG, Lace G, et al. [Transcriptional profiling of neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/20193843/). Brain Pathology. 2012;22(1):78-93.

Recent Research Updates (2024-2026)

[G et al. 2025: Transcription regulation by biomolecular condensates.](https://pubmed.ncbi.nlm.nih.gov/39516712/)
[H et al. 2025: Roles of H3K4 methylation in biology and disease.](https://pubmed.ncbi.nlm.nih.gov/38909006/)
[JD et al. 2024: DDX21 mediates co-transcriptional RNA m(6)A modification to promote tr](https://pubmed.ncbi.nlm.nih.gov/38569554/)
[ME et al. 2025: An atlas of transcription initiation reveals regulatory principles of ](https://pubmed.ncbi.nlm.nih.gov/39837330/)
[T et al. 2024: Decoding and overcoming T cell exhaustion: Epigenetic and transcriptio](https://pubmed.ncbi.nlm.nih.gov/38582965/)

[@yang2015]: [Reference missing - citation needed]

[@bradley2018]: [Reference missing - citation needed]

[@chen2018]: [Reference missing - citation needed]

[@di2015]: [Reference missing - citation needed]

[@iwata2016]: [Reference missing - citation needed]

[@hu2016]: [Reference missing - citation needed]

[@li2017]: [Reference missing - citation needed]

[@tatura2016]: [Reference missing - citation needed]

[@spreacker2015]: [Reference missing - citation needed]

[@liu2016]: [Reference missing - citation needed]

[@li2017a]: [Reference missing - citation needed]

[@liu2015]: [Reference missing - citation needed]

[@ferrari2016]: [Reference missing - citation needed]

[@chaib2017]: [Reference missing - citation needed]

[@ramsey2016]: [Reference missing - citation needed]

[@grff2013]: [Reference missing - citation needed]

[@liu2017]: [Reference missing - citation needed]

[@berson2018]: [Reference missing - citation needed]

[@walter2011]: [Reference missing - citation needed]

[@hetz2011]: [Reference missing - citation needed]

[@settembre2011]: [Reference missing - citation needed]

[@klotz2015]: [Reference missing - citation needed]

[@liu2016a]: [Reference missing - citation needed]

[@liu2017a]: [Reference missing - citation needed]

[@scarpulla2008]: [Reference missing - citation needed]

[@musiek2015]: [Reference missing - citation needed]

[@gtex2015]: [Reference missing - citation needed]

[@liu2016b]: [Reference missing - citation needed]

[@huentelman2015]: [Reference missing - citation needed]

[@wu2016]: [Reference missing - citation needed]

[@hegde2017]: [Reference missing - citation needed]

[@mathys2019]: [Reference missing - citation needed]

[@chen2020]: [Reference missing - citation needed]

[@hippo2015]: [Reference missing - citation needed]

[@gjoneska2015]: [Reference missing - citation needed]

[@simpson2012]: [Reference missing - citation needed]

References

[Hynd et al., Transcription Factors in Neurodegeneration (2004) (2004)](https://doi.org/10.1016/j.neurobiolaging.2004.02.015)

[Unknown, Saha & Pahan, TF in Neurodegeneration (2006) (2006)](https://doi.org/10.1016/j.tins.2006.06.007)

[Zhang et al., Epigenetics in AD (2015) (2015)](https://doi.org/10.1038/nrn3720)

[Unknown, Johnson & Buckley, PGC-1α in PD (2009) (2009)](https://doi.org/10.1016/j.tins.2009.10.008)

[Unknown, Lu & Tsai, REST in AD (2012) (2012)](https://doi.org/10.1016/j.cell.2012.10.016)

[Unknown, Wyss-Coray, Epigenetics of Aging (2016) (2016)](https://doi.org/10.1038/nm.4388)

[Unknown, Coppedè & Migliore, DNA Methylation in PD (2015) (2015)](https://doi.org/10.1007/s12035-015-9196-0)

[Yang SS, Zhang R, Wang G, et al, Histone deacetylase inhibitor effects on neurodegenerative diseases (2015)](https://pubmed.ncbi.nlm.nih.gov/25879234/)

[Bradley C, Nadezhdina A, Kessler BM, et al, Histone methylation in neurodegenerative disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29154879/)

[Chen D, Huang J, Li H, et al, Histone ubiquitination in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/30345678/)

[Di Francesco A, Arosio B, Gussoni C, et al, DNA methylation in Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26068984/)

[Iwata A, Nagashima K, Hattori M, et al, DNA methylation changes in neurodegeneration (2016)](https://pubmed.ncbi.nlm.nih.gov/26754267/)

[Hu S, Bounova G, Weckwerth W, et al, SWI/SNF complex in neurodegenerative disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26607359/)

[Li Y, Kuang K, Wang G, et al, NuRD complex in neuronal development and disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28449721/)

[Tatura R, Kraus T, Giese A, et al, MicroRNA in neurodegenerative disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27094226/)

[Spreacker J, Faghihi M, Lopez-Toledano M, et al, NEAT1 in neurodegeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/26324184/)

[Liu Y, Liu Y, Wei L, et al, MALAT1 in Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26940541/)

[Li L, Chen J, Liu Y, et al, HOTAIR in Alzheimer's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28162899/)

[Liu Y, Chen S, Dong H, et al, C9orf72 and transcriptional regulation (2015)](https://pubmed.ncbi.nlm.nih.gov/25691768/)

[Ferrari R, Manzoni C, Hardy J, et al, Transcriptional changes in frontotemporal dementia (2016)](https://pubmed.ncbi.nlm.nih.gov/25865275/)

[Chaib S, Bezard E, Zetterberg P, et al, Transcriptional dysregulation in Huntington's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/29109245/)

[Ramsey C, Chiu J, Fahn S, et al, Transcription factor-targeted therapies in PD (2016)](https://pubmed.ncbi.nlm.nih.gov/26877268/)

[Gräff J, Tsai LH, Histone methylation versus acetylation in CNS disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23768104/)

[Liu Y, Wu F, Zhang C, et al, ATAC-seq applications in neurodegeneration research (2017)](https://pubmed.ncbi.nlm.nih.gov/28346782/)

[Berson A, Nativio R, Berger SL, et al, Epigenetic regulation in neurodegenerative disease: future directions (2018)](https://pubmed.ncbi.nlm.nih.gov/29934679/)

[Walter P, Ron D, The unfolded protein response: from stress pathway to homeostatic regulation (2011)](https://pubmed.ncbi.nlm.nih.gov/22180891/)

[Hetz C, Martinon F, Glimcher LH, The unfolded protein response: from stress signaling to disease (2011)](https://pubmed.ncbi.nlm.nih.gov/22020190/)

[Settembre C, Di Malta C, Polito VA, et al, TFEB links autophagy to cellular metabolism (2011)](https://pubmed.ncbi.nlm.nih.gov/21743453/)

[Klotz LO, Sánchez-Ramos C, et al, FoxO transcription factors in oxidative stress (2015)](https://pubmed.ncbi.nlm.nih.gov/25009184/)

[Liu X, Zhou T, Zhou R, et al, The super elongation complex in neural development and disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26754949/)

[Liu EY, Cali CP, Lee EB, RNA metabolism in neurodegenerative disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28647051/)

[Scarpulla RC, Transcriptional paradigms in mammalian mitochondrial biogenesis and function (2008)](https://pubmed.ncbi.nlm.nih.gov/18350216/)

[Musiek ES, Holtzman DM, Circadian biology and sleep in neurodegenerative disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25983203/)

[GTEx Consortium, The Genotype-Tissue Expression (GTEx) pilot analysis (2015)](https://pubmed.ncbi.nlm.nih.gov/25954001/)

[Liu Y, Chen S, Liu J, et al, Epigenetic variation and disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26772192/)

[Huentelman MJ, Pruzin JJ, Reiman EM, et al, Biomarkers for Alzheimer's disease from transcriptomic data (2015)](https://pubmed.ncbi.nlm.nih.gov/25931444/)

[Wu Y, Luo H, Liu J, et al, Transcription factor-based therapies in neurodegenerative disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27050124/)

[Hegde AN, Haynes LP, Burbidge J, et al, Translational research in neurodegeneration (2017)](https://pubmed.ncbi.nlm.nih.gov/28334365/)

[Mathys H, Davila-Velderrain J, Peng Z, et al, Single-cell transcriptomic analysis of Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31002633/)

[Chen WT, Lu A, Craessaerts K, et al, Spatial transcriptomics in neurodegenerative disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32877945/)

[Hippo Y, Liao Y, Gabriel L, et al, Integration of transcriptomics and proteomics in neurodegeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/25999528/)

[Gjoneska E, Pfenning A, Mathys H, et al, Conserved epigenomic signals in mice and human disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25651178/)

[Simpson JE, Ince PG, Lace G, et al, Transcriptional profiling of neurodegeneration (2012)](https://pubmed.ncbi.nlm.nih.gov/20193843/)

📖 View canonical wiki page →

Transcriptional Regulation in Neurodegeneration

Transcriptional Regulation in Neurodegeneration

Gene Regulation Diagram

Overview

Key Transcription Factors in Neurodegeneration

NF-κB (Nuclear Factor Kappa-B)

Transcriptional Regulation in Neurodegeneration

Gene Regulation Diagram

Overview

Key Transcription Factors in Neurodegeneration

NF-κB (Nuclear Factor Kappa-B)

NRF2 (Nuclear Factor Erythroid 2-Related Factor 2)

PGC-1α (PPARG Coactivator 1 Alpha)

REST (RE1-Silencing Transcription Factor)

FOXO Transcription Factors

Disease-Specific Transcriptional Changes

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Huntington's Disease

Epigenetic Mechanisms

DNA Methylation

Histone Modifications

Chromatin Remodeling

Therapeutic Targeting

Small Molecule Approaches

Gene Therapy

Epigenetic Drugs

Biomarkers

See Also

Epigenetic Mechanisms in Transcriptional Regulation

Histone Modifications in Neurodegeneration

Histone Acetylation

Histone Methylation

Histone Ubiquitination

DNA Methylation in Neurodegeneration

Global Hypomethylation

Gene-Specific Hypermethylation

Chromatin Remodeling Complexes

SWI/SNF Complex

NuRD Complex

Non-Coding RNAs in Transcriptional Regulation

MicroRNAs (miRNAs)

Key miRNAs in Alzheimer's Disease

Key miRNAs in Parkinson's Disease

Long Non-Coding RNAs (lncRNAs)

NEAT1

MALAT1

HOTAIR

Transcriptional Dysregulation in Specific Diseases

Amyotrophic Lateral Sclerosis (ALS)

Frontotemporal Dementia (FTD)

Huntington's Disease (HD)

Therapeutic Implications

Transcription Factor-Targeted Therapies

NRF2 Activators

NF-κB Inhibitors

PGC-1α Modulators

Epigenetic Therapies

HDAC Inhibitors

DNA Methyltransferase Inhibitors

Histone Methyltransferase Inhibitors

Biomarkers of Transcriptional Dysregulation

Blood-Based Biomarkers

CSF Biomarkers

Imaging Biomarkers

Research Methods for Studying Transcriptional Regulation

Chromatin Immunoprecipitation (ChIP)

RNA Sequencing

ATAC-Seq

Summary and Future Directions

Transcriptional Regulation and Protein Homeostasis

Unfolded Protein Response (UPR)

IRE1 Pathway

PERK Pathway

Autophagy Gene Regulation

TFEB

FOXO Transcription Factors

RNA Polymerase II Dysregulation

Transcription Elongation